BridgeBio director exercises options, sells 64,921 shares

BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade. On March 4, 2026, Ellis exercised options for 64,921 shares of common stock at $8.45 per share, converting a previously held stock option that had vested in three annual installments beginning on June 22, 2023 and ending on June 22, 2025. The same day, Ellis sold 64,921 shares of common stock at a weighted average price of $64.8681 per share, within a range of $64.255 to $65.21, under a Rule 10b5‑1 sales plan adopted on December 3, 2025, and held 18,589 shares directly afterward.

Insider Trade Summary

Exercise and Sale: 64,921 shares ($3.66M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ellis Andrea

Role Director

Sold 64,921 shs ($4.21M)

Approx. gross sale proceeds $4.21M

Approx. exercise cost $549K

Approx. pre-tax spread $3.66M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	64,921	$0.00	$0.00
Exercise	Common Stock	64,921	$8.45	$549K
Sale	Common Stock	64,921	$64.8681	$4.21M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 18,589 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.
2. F2. Represents the weighted average sale price of the shares sold from $64.255 to $65.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

FAQ

What insider transactions did BBIO director Andrea Ellis report?

Andrea Ellis exercised options for 64,921 BridgeBio Pharma shares and sold 64,921 common shares on March 4, 2026. These transactions converted vested stock options into stock and then into cash while leaving her with 18,589 directly held shares afterward.

How many BridgeBio (BBIO) shares did Andrea Ellis sell and at what price?

Andrea Ellis sold 64,921 BridgeBio common shares at a weighted average price of $64.8681 per share. The sale prices ranged from $64.255 to $65.21, as disclosed, with detailed trade‑level pricing available upon request to the company or regulators.

Was the BBIO insider sale by Andrea Ellis under a Rule 10b5-1 plan?

Yes. The sale of 64,921 BridgeBio shares was executed under a Rule 10b5‑1 trading plan adopted by Andrea Ellis on December 3, 2025. Such plans prearrange trading terms, helping separate trading decisions from later market or company developments.

What stock options did Andrea Ellis exercise in this BBIO Form 4?

Andrea Ellis exercised a stock option covering 64,921 BridgeBio shares at $8.45 per share on March 4, 2026. The option vested in three equal annual installments between June 22, 2023 and June 22, 2025, contingent on continued board service during that period.

How many BridgeBio (BBIO) shares does Andrea Ellis hold after these transactions?

Following the March 4, 2026 option exercise and share sale, Andrea Ellis directly holds 18,589 BridgeBio common shares. This balance reflects the acquisition of 64,921 shares via option exercise and the subsequent sale of the same number of shares that day.

What does transaction code M mean in the BBIO Form 4 for Andrea Ellis?

Transaction code M in Andrea Ellis’s Form 4 indicates the exercise or conversion of a derivative security, here a stock option. It records acquiring 64,921 BridgeBio common shares from an option with a $8.45 exercise price before those shares were sold the same day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellis Andrea

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		64,921	A	$8.45	83,510	D
Common Stock	03/04/2026		S(1)		64,921	D	$64.8681(2)	18,589	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.45	03/04/2026		M			64,921	(3)	06/22/2032	Common Stock	64,921	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.

2. Represents the weighted average sale price of the shares sold from $64.255 to $65.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.